Key Players
Competitive Landscape
Competition includes broad imaging manufacturers, specialist elastography providers and diagnostic-platform companies. Suppliers are evaluated through measurement reproducibility, workflow fit, evidence quality and the ability to connect an initial result with referral, monitoring or drug-development decisions.
Recent activity has moved in two directions: ultrasound upgrades that add quantitative liver assessment, and blood-based algorithms that structure fibrosis risk. Philips announced AI-assisted workflow and quantitative measurement functions in February 2025, FUJIFILM Healthcare Europe added EUS-guided liver assessment in October 2025 and Roche launched its Liver Disease Panel in May 2026. Buyers still compare price, but technical validation and pathway fit increasingly shape shortlists.
Company developments mapped to drivers, trends and opportunities (2026-2036)
| Development | Driver | Trend | Opportunity |
|---|---|---|---|
| Philips announced AI-assisted workflow and quantitative measurement functions for EPIQ Elite and Affiniti in February 2025. | Clinicians need repeatable measurements within familiar ultrasound workflows. | Quantitative imaging is being combined with workflow automation. | Software upgrades, elastography adoption and repeat monitoring. |
| FUJIFILM Healthcare Europe announced an ARIETTA 850 FF ENDO upgrade in October 2025. | Specialists need liver assessment during endoscopic ultrasound procedures. | EUS platforms are adding attenuation measurement and 2D shear-wave elastography. | Procedure-linked assessment and specialist workflow integration. |
| Roche launched the Liver Disease Panel in May 2026. | Care pathways need structured fibrosis risk assessment from routine clinical data. | Certified algorithms are joining laboratory markers and referral workflows. | Algorithm distribution, laboratory integration and longitudinal management. |
GE HealthCare, Siemens Healthineers, Canon Medical Systems, Echosens, Hologic, Abbott Laboratories and BioMérieux SA remain in the assessed company set outside the three mapped developments.
Source: Future Market Insights, Non-Invasive Diagnostics for Fibrotic Diseases Market report, 2026-2036.
Imaging suppliers compete through stiffness measurement and multiparametric assessment, while specialist and diagnostic-platform companies compete through standardization, algorithms and workflow integration. Product approvals and registrations apply only to the named product, entity or market.
Who leads the Non-Invasive Diagnostics for Fibrotic Diseases Market?
No revenue leader is assigned in this evidence comparison. GE HealthCare, Siemens Healthineers, Canon Medical Systems, FUJIFILM Healthcare, Philips Healthcare, Echosens, Hologic, Roche Diagnostics, Abbott Laboratories and BioMérieux SA are compared by documented market-relevant capabilities rather than corporate scale.
Which suppliers have documented approvals?
Roche states that its Liver Disease Panel contains certified algorithms, and LiverPRO is CE-certified for fibrosis risk assessment in defined adult populations. Other approvals or registrations remain product-specific. No common certification is assigned across the full supplier set.
Which companies provide imaging systems products or services?
GE HealthCare, Siemens Healthineers, Canon Medical Systems, FUJIFILM Healthcare and Philips Healthcare provide broad imaging or ultrasound routes. Echosens and Hologic add specialist elastography capabilities for liver stiffness assessment.
Which suppliers serve USA and South Korea?
The primary sources reviewed establish multi-market or global activity for several suppliers, but they do not provide a complete supplier-by-supplier map for both the USA and South Korea. Geographic reach should therefore be confirmed against current product registrations, local distribution and service coverage before procurement.
Representative Company Overview
| Company | Positioning | Verified market-relevant capabilities |
|---|---|---|
| GE HealthCare | Imaging / Elastography | LOGIQ ultrasound and liver assessment workflows. |
| Siemens Healthineers | Imaging / Elastography | Virtual Touch ARFI and shear-wave elastography. |
| Canon Medical Systems | Imaging / Elastography | Multiparametric ultrasound liver analysis and shear-wave elastography. |
| FUJIFILM Healthcare | Imaging / Elastography | RTE, SWM and SWE functions for non-invasive liver assessment. |
| Philips Healthcare | Imaging / Elastography | ElastQ and Auto ElastQ liver stiffness assessment. |
| Echosens | Specialist Liver Assessment | FibroScan VCTE for fibrosis and steatosis assessment and monitoring. |
| Hologic, Inc. | Specialist Elastography | Real-time ShearWave Elastography for liver fibrosis staging. |
| Roche Diagnostics | Biomarker / Algorithm | Liver Disease Panel, LiverPRO and Elecsys PRO-C3. |
| Abbott Laboratories | Diagnostic Platform | Included in the assessed company set; no exact-market capability rating assigned. |
| BioMérieux SA | Diagnostic Platform | Included in the assessed company set; no exact-market capability rating assigned. |
Research Methodology
The companies here show how competition is structured rather than ranking revenue or market share. Inclusion requires official evidence of products, services, approvals, algorithms, programs or operating scope within the market definition. Evidence comes from company material, product literature, filings, regulatory actions and official announcements. Registrations belong to the entity or site that holds them. Capability claims are limited to the public evidence reviewed for this article and do not imply wider group certification. Geographic reach records documented activity only. Technology shares are FMI estimates for 2026 and remain separate from supplier-positioning evidence.
